ZBIO
HEALTHCAREZenas Biopharma Inc
$20.83+0.07 (+0.34%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving ZBIO Today?
No stock-specific AI insight has been generated for ZBIO yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$8.54$44.60
$20.83
Fundamentals
Market Cap$1.3B
P/E Ratio—
EPS$-8.44
Dividend Yield—
Dividend / Share—
ROE-1.4%
Profit Margin—
Debt / Equity—
Trading
Volume353K
Avg Volume (10D)—
Shares Outstanding62.4M
ZBIO News
21 articles- IgG4-Related Disease Market Analysis and Forecasts, 2025-2026 & 2035 with Amgen, Zenas BioPharma, Bristol Myers Squibb, and Sanofi LeadingYahoo Finance·May 7, 2026
- Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Yahoo Finance·Apr 17, 2026
- Insiders Are Scooping Up These 2 ‘Strong Buy’ StocksYahoo Finance·Apr 8, 2026
- InnoCare Hits Profit Milestone, Relative Undervaluation Points To Stock UpsideBenzinga·Mar 30, 2026
- Zenas BioPharma Funding Shifts Focus From Survival Risk To Execution RiskYahoo Finance·Mar 29, 2026
- Sector Update: Health Care Stocks Softer Late AfternoonYahoo Finance·Mar 27, 2026
- Sector Update: Health Care Stocks Retreat Friday AfternoonYahoo Finance·Mar 27, 2026
- Wall Street Set to Open Lower in Friday Trading; Investors Not Assuaged by US Deadline Extension for Iran to Open Strait of HormuzYahoo Finance·Mar 27, 2026
- Zenas BioPharma Announces Pricing of Concurrent Public Offerings of 2.50% Convertible Senior Notes Due 2032 and Common Stock with Aggregate Gross Proceeds of $300.0 MillionGlobeNewswire Inc.·Mar 27, 2026
- Zenas BioPharma Announces Proposed Concurrent Public Offerings of Convertible Senior Notes Due 2032 and Common StockYahoo Finance·Mar 26, 2026
- ENAVATE's Zenas Bio Pharma add Is a Footnote — The Obexelimab Pipeline Is What to WatchMotley Fool·Mar 21, 2026
- Zenas BioPharma Funding Supports Obexelimab Plans After Pullback In SharesYahoo Finance·Mar 17, 2026
- Zenas BioPharma Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate UpdateYahoo Finance·Mar 16, 2026
- CD19 Inhibitors Market to Witness Significant Expansion During the Forecast Period (2025-2034) as Autoimmune and Oncology Pipelines Accelerate | DelveInsightYahoo Finance·Mar 10, 2026
- Zenas BioPharma, Inc. (ZBIO): A Bull Case TheoryYahoo Finance·Feb 28, 2026
- Encouraging Phase II Trial Data Supported Zenas BioPharma (ZBIO) in Q4Yahoo Finance·Feb 19, 2026
- Why Zenas BioPharma (ZBIO) Is Up 24.6% After Obexelimab’s Phase 2 MS Trial Success - And What's NextYahoo Finance·Feb 18, 2026
- Zenas BioPharma Highlights Obexelimab Phase 3 Win, Targets Q2 BLA Filing at Guggenheim SummitMarketbeat·Feb 16, 2026
- Zenas BioPharma Announces Late-Breaking Platform Presentation of Results from Phase 2 MoonStone Trial of Obexelimab in Relapsing Multiple Sclerosis at ACTRIMS Forum 2026Yahoo Finance·Feb 9, 2026
- Zenas BioPharma to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026Yahoo Finance·Feb 4, 2026
- Zenas BioPharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)Yahoo Finance·Jan 16, 2026
All 21 articles loaded
Price Data
Open$0.00
Previous Close$20.76
Day High$0.00
Day Low$0.00
52 Week High$44.60
52 Week Low$8.54
52-Week Range
$8.54$44.60
$20.83
Fundamentals
Market Cap$1.3B
P/E Ratio—
EPS$-8.44
Dividend Yield—
Dividend / Share—
ROE-1.4%
Profit Margin—
Debt / Equity—
Trading
Volume353K
Avg Volume (10D)—
Shares Outstanding62.4M
About Zenas Biopharma Inc
Zenas BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of transformative immunology-based therapies. The company is headquartered in Waltham, Massachusetts.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—